| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.16.8.1209 |
| P698 | PubMed publication ID | 17685870 |
| P2093 | author name string | Rafael Simó | |
| Cristina Hernández | |||
| P2860 | cites work | Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth | Q24561921 |
| Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen | Q27620162 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy | Q28257133 | ||
| Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization | Q28504628 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor | Q30631779 | ||
| Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin | Q30686422 | ||
| Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. | Q30824036 | ||
| The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study | Q30881124 | ||
| Human retinal molecular weight exclusion limit and estimate of species variation | Q30919500 | ||
| Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model | Q31017435 | ||
| Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy | Q31065469 | ||
| Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization | Q31081886 | ||
| Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization | Q31101634 | ||
| The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane | Q31121737 | ||
| Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study | Q31148660 | ||
| Adeno-associated virus-mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy | Q45422910 | ||
| Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated | Q45713445 | ||
| Gene therapy for ocular neovascularization: a cure in sight | Q45862681 | ||
| Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy | Q46458778 | ||
| Vascular endothelial growth factor expression and secretion by retinal pigment epithelial cells in high glucose and hypoxia is protein kinase C-dependent | Q46464111 | ||
| A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema | Q46695946 | ||
| Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals | Q46847276 | ||
| The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank | Q46857067 | ||
| Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration | Q46861254 | ||
| Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients | Q46872527 | ||
| Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial | Q46924646 | ||
| Testing intravitreal toxicity of bevacizumab (Avastin). | Q46969338 | ||
| Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study | Q46969343 | ||
| The 14-year incidence of visual loss in a diabetic population | Q47971799 | ||
| Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases | Q48500148 | ||
| Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. | Q52189548 | ||
| Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. | Q52537902 | ||
| The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. | Q53851117 | ||
| Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. | Q54574472 | ||
| Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. | Q54611983 | ||
| Association of macular involvement with proliferative retinopathy in Type 2 diabetes | Q31938618 | ||
| VEGF localisation in diabetic retinopathy | Q32035851 | ||
| Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. | Q32073544 | ||
| Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial | Q33199467 | ||
| Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization | Q33206194 | ||
| Diabetic macular edema: classification, medical and laser therapy | Q33208471 | ||
| Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys | Q33219678 | ||
| Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization | Q33235072 | ||
| EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. | Q33237979 | ||
| Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. | Q33316526 | ||
| Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site | Q33696019 | ||
| Mitogen-activated protein kinases as glucose transducers for diabetic complications | Q33767966 | ||
| Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins | Q33775844 | ||
| Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy | Q33826397 | ||
| The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. | Q34300405 | ||
| Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate | Q34369354 | ||
| Review: practical issues in intravitreal drug delivery | Q34381545 | ||
| Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects | Q34436945 | ||
| Protein kinase C activation and the development of diabetic complications | Q34469779 | ||
| Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 | ||
| The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration | Q34571631 | ||
| Retinal repair by transplantation of photoreceptor precursors | Q34580415 | ||
| Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 | ||
| Novel approaches for retinal drug delivery. | Q34998854 | ||
| Gene therapy for ocular angiogenesis. | Q35061497 | ||
| Recent developments in ocular gene therapy | Q35125708 | ||
| Adeno-associated viral vectors for retinal gene transfer. | Q35566831 | ||
| Neural progenitor cells from postmortem adult human retina | Q35592738 | ||
| Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo | Q35747338 | ||
| Drug delivery systems for vitreoretinal diseases | Q35792000 | ||
| Inhibitors of ocular neovascularization: promises and potential problems. | Q36077697 | ||
| Novel approaches in the treatment of angiogenic eye disease | Q36196664 | ||
| New and improved glucocorticoid receptor ligands | Q36322079 | ||
| Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis | Q36323799 | ||
| The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. | Q36376700 | ||
| Ten years after the Diabetic Retinopathy Study | Q36447047 | ||
| Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors | Q36496079 | ||
| Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. | Q36608661 | ||
| Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy | Q36608675 | ||
| Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation | Q37307370 | ||
| Facile isolation and the characterization of human retinal stem cells | Q37595539 | ||
| Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. | Q39737660 | ||
| VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. | Q40595312 | ||
| A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. | Q40662746 | ||
| Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties | Q40708169 | ||
| SDF-1 is both necessary and sufficient to promote proliferative retinopathy. | Q40743408 | ||
| Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids | Q41119110 | ||
| Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration | Q41697326 | ||
| Pharmacologically regulated gene expression in the retina following transduction with viral vectors | Q43583263 | ||
| Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy | Q43664044 | ||
| Topical application of integrin antagonists inhibits proliferative retinopathy | Q43664047 | ||
| Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats | Q43664189 | ||
| Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy | Q43722785 | ||
| Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment | Q43724422 | ||
| Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. | Q43808927 | ||
| A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus | Q43877928 | ||
| Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration | Q43943551 | ||
| Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization | Q44013450 | ||
| Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis | Q44081378 | ||
| Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. | Q44088681 | ||
| Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes | Q44112573 | ||
| Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. | Q44128315 | ||
| Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy | Q44230956 | ||
| Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy | Q44231069 | ||
| Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model | Q44305181 | ||
| Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier | Q44340120 | ||
| Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization | Q44401505 | ||
| Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema | Q44586436 | ||
| Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity | Q44669160 | ||
| Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes | Q44686998 | ||
| Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. | Q44763476 | ||
| Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. | Q44777388 | ||
| Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia | Q44793956 | ||
| The effect of angiostatin on vascular leakage and VEGF expression in rat retina | Q44849251 | ||
| Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice | Q44956667 | ||
| Isolation of retinal progenitor cells from post-mortem human tissue and comparison with autologous brain progenitors. | Q44973920 | ||
| Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats | Q44982994 | ||
| Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells | Q45068998 | ||
| Pegaptanib for neovascular age-related macular degeneration | Q45206481 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1209-1226 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice | |
| P478 | volume | 16 |
| Q36358667 | Adenoviral 15-lipoxygenase-1 gene transfer inhibits hypoxia-induced proliferation of retinal microvascular endothelial cells in vitro |
| Q37476639 | Angiogenesis in the kidney: a new therapeutic target? |
| Q38608755 | Clinical characteristics and risk factors for retinal diabetic neurodegeneration in type 2 diabetes. |
| Q33305305 | Fenofibrate for diabetic retinopathy |
| Q42034969 | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
| Q27332433 | Inhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-γ and down-regulation of VEGFR-2 expression |
| Q37135388 | Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy |
| Q51301114 | Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness. |
| Q33360791 | Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation |
| Q39009395 | Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy |
| Q26774386 | Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application |
| Q38211670 | Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy |
| Q33887925 | Neurodegeneration: An early event of diabetic retinopathy |
| Q38009713 | Neuroprotection in diabetic retinopathy |
| Q36458943 | Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression |
| Q35600275 | Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage |
| Q41377127 | S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression |
| Q28471888 | Selective inhibition of retinal angiogenesis by targeting PI3 kinase |
| Q37000724 | Silencing of S100A4, a metastasis-associated protein, inhibits retinal neovascularization via the downregulation of BDNF in oxygen-induced ischaemic retinopathy |
| Q38195792 | Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives |
| Q46081402 | Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy |
| Q34100527 | The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy. |
| Q34426246 | Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy |
| Q38293676 | Vitreous humor in the pathologic scope: insights from proteomic approaches. |
Search more.